Shilajit for Heart and Vascular Health After Menopause: What the Research Shows

Start with what the evidence cannot claim. Shilajit is not a cardiac medication, and no clinical trial has tested it as one. Positioning it that way would misrepresent what the research actually shows.

What the research does show is something more specific. Multiple studies have measured the biological mechanisms that menopause disrupts in the cardiovascular system and found that shilajit supplementation moved them in the right direction. Lipid panels improved. Inflammation markers fell. Endothelial function got better. These are the upstream conditions that cardiovascular health depends on, and they are the correct framing for what shilajit does and does not do.

What menopause does to heart health

Before menopause, women have significantly better cardiovascular risk profiles than men of the same age. After menopause, that advantage erodes. Within a decade of the final menstrual period, women's cardiovascular risk approaches and then surpasses men's in the same age group. The shift is biological, not coincidental, and it runs almost entirely through estrogen.

Estrogen supports the production of nitric oxide, the molecule that signals artery walls to stay flexible and responsive to blood flow. It regulates cholesterol metabolism, keeping LDL lower and HDL higher than they would otherwise be. It acts as an antioxidant in the endothelial cells that line artery walls, protecting them from oxidative damage. And it maintains a vascular environment that resists the kind of chronic, low-grade inflammation that builds up over years.

When estrogen signaling drops at menopause, all of these protective effects weaken at once. LDL tends to rise. HDL tends to fall. Triglycerides increase. Inflammatory markers like high-sensitivity C-reactive protein (hsCRP) climb. Arterial stiffness increases. Endothelial cells, deprived of their antioxidant support, accumulate damage that impairs their ability to produce nitric oxide. These changes are measurable within months of menopause and compound over years.

The lipid evidence

The most detailed study on shilajit's effect on cardiovascular risk markers was conducted by Niranjan et al. and published in the International Journal of Ayurveda and Pharma Research. The 12-week randomized controlled trial enrolled 40 adults with type-2 diabetes and compared purified shilajit supplementation against a control group.

The results across the lipid panel were substantial. LDL cholesterol dropped by 13 percent in the shilajit group. Total cholesterol fell by 21 percent. Triglycerides declined by 16 percent. HDL cholesterol, the protective lipoprotein, rose by 14 percent. Beyond the lipid panel, the study measured inflammation directly. High-sensitivity C-reactive protein fell in the shilajit group. Malondialdehyde, a marker of oxidative damage in cell membranes, also fell. Endothelial function improved. (https://ijapr.in/index.php/ijapr/article/view/322)

The honest caveat matters here. The trial was conducted in adults with type-2 diabetes, not in postmenopausal women. Diabetes produces endothelial dysfunction and lipid dysregulation through its own mechanisms. The biological targets the study measured, oxidative stress, lipid balance, and endothelial function, are the same targets that menopause disrupts through different pathways. The results are relevant but not a direct translation, and the sample size of 40 is small. A single trial does not settle a question, even when the results are compelling.

The endothelial function evidence

A randomized controlled trial published in the Indian Journal of Physiology and Pharmacology enrolled elderly adults with hypertension and tested purified shilajit against placebo. The researchers measured oxidative stress markers, arterial stiffness, and endothelial function directly. The shilajit group showed significant reductions in oxidative stress and meaningful improvements in both endothelial function and arterial stiffness compared to placebo. (https://ijpp.com/effect-of-purified-shilajit-asphaltum-punjabianum-on-oxidative-stress-arterial-stiffness-and-endothelial-function-in-elderly-with-hypertension-a-randomised-controlled-study/)

A 2025 randomized controlled trial by Martinez et al., published in Nutrients, tested a combination of chromium, Phyllanthus emblica, and shilajit alongside an exercise and diet program in 166 adults. The combination group showed improvements in vascular function, insulin sensitivity, lipid markers, and body composition compared to controls. The important nuance is that shilajit was one of three active compounds in the treatment arm. It is not possible to attribute the results to shilajit alone based on that design. The study supports the combination as tested, not shilajit in isolation. (PMID 40573153. https://pubmed.ncbi.nlm.nih.gov/40573153/)

How the mechanism works

Fulvic acid, the primary active compound in shilajit, appears to affect cardiovascular risk through three overlapping pathways.

The first is antioxidant protection of the vascular endothelium. A 2018 review by Winkler and Ghosh in the Journal of Diabetes Research examined the research on fulvic acid's mechanisms and found evidence for reduction of TNF-alpha, a key driver of vascular inflammation, and improvement in oxidative stress markers. (https://pmc.ncbi.nlm.nih.gov/articles/PMC6151376/) Oxidative damage in endothelial cells is one of the main reasons those cells cannot produce nitric oxide efficiently. Reducing that burden directly supports vascular function.

The second is estrogen signaling support. Shilajit is not a hormone. It does not replace estrogen or deliver it to the body. What the fulvic acid in it appears to do is support the body's own estrogen signaling pathway. Estrogen receptors exist throughout the cardiovascular system, including in endothelial cells, and their activation influences nitric oxide production, lipid metabolism, and oxidative stress management. When signaling through those receptors strengthens even modestly, the downstream effects include more active nitric oxide production and better lipid regulation.

The third is trace mineral delivery. Shilajit contains more than 80 trace minerals in a form that fulvic acid helps carry into cells. Magnesium is involved in arterial smooth muscle relaxation and blood vessel tone. Selenium functions as an antioxidant cofactor in endothelial cells. These minerals are commonly deficient in postmenopausal women, and deficiencies in both are associated with worse cardiovascular outcomes.

Understanding the evidence as it stands

The cardiovascular case for shilajit rests on a cluster of findings rather than a single landmark trial. The Niranjan lipid data is real and meaningful. The endothelial function improvements across multiple study populations are consistent. The mechanism through fulvic acid's antioxidant effects and estrogen signaling support is plausible and documented.

What does not yet exist is a large, well-powered randomized controlled trial in postmenopausal women specifically, designed with cardiovascular outcomes as the primary endpoint. That is the study that would settle the question with confidence.

What the current evidence supports is this: shilajit supplementation has shown consistent improvements in the biological markers that predict cardiovascular risk, including lipid panels, inflammation markers, and endothelial function, across multiple study populations. For postmenopausal women who are paying attention to their cardiovascular trajectory, that cluster of findings is worth knowing about.

For women with a breast cancer history

Shilajit is not a hormone and does not work like estrogen replacement. The concern about estrogen and estrogen-sensitive cancers applies specifically to synthetic estrogen, not to compounds that support the body's natural signaling.

On the research side, a study published in Nutrients found that shilajit inhibited MCF-7 and MDA-MB-231 breast cancer cells and induced apoptosis while leaving normal breast cells unharmed. (PMID 34466597. https://pubmed.ncbi.nlm.nih.gov/34466597/) MCF-7 is the estrogen-receptor-positive breast cancer cell line used most commonly in research. The finding points away from the direction a synthetic estrogen product would point.

This is cell culture research, not a clinical trial. But the distinction between supporting estrogen signaling and delivering synthetic estrogen is real and mechanistically significant.

Safety and what matters in a product

Zero serious adverse events have ever been reported across any human shilajit study.

Shilajit forms inside rock and can carry geological contaminants from the source region if it is not properly processed. Independent third-party lab testing for heavy metals and mycotoxins, with results published as a certificate of analysis, is not optional. It is the baseline. The fulvic acid percentage matters too. Most of the cardiovascular research was conducted with higher-concentration preparations, and the certificate of analysis should confirm the fulvic acid content rather than just claim one.

What this means for you

Menopause changes the cardiovascular picture for women in specific, measurable ways. The estrogen signaling that kept arteries flexible, lipid panels balanced, and endothelial cells functioning does not carry forward unchanged.

The shilajit research has tested several of the mechanisms involved and found improvements. Lipid markers moved in the right direction. Oxidative stress fell. Endothelial function improved. This is not a cardiovascular treatment, and it is not a substitute for diet, exercise, or medication. It is a researched intervention targeting the biological pathways that menopause disrupts.

Optimum Shilajit Trifecta combines purified shilajit from the Altai mountains with pearl powder and bamboo silica. Independently third-party lab tested for heavy metals and mycotoxins, with the certificate of analysis on the website. A family-owned company out of Florida. They do not sell on Amazon and do not wholesale.

Frequently asked questions

Does shilajit lower cholesterol?

A 12-week trial found LDL down 13 percent, total cholesterol down 21 percent, triglycerides down 16 percent, and HDL up 14 percent in adults with type-2 diabetes. This was one 40-person trial, not a settled clinical conclusion, but the signal is strong enough to take seriously.

Is shilajit safe if I take statins or blood pressure medication?

The human safety record across published trials is excellent, with zero serious adverse events reported. There are no documented interactions with statins or antihypertensive medications in the research literature. If you are on multiple medications, review any new supplement with the prescribing clinician based on your specific profile.

What makes shilajit relevant to heart health specifically?

The cardiovascular effects that menopause produces — lower HDL, higher LDL and triglycerides, worse endothelial function, more arterial stiffness — are the specific markers the shilajit research has measured and found improvements in. The mechanism runs through fulvic acid's antioxidant effects and support for the body's estrogen signaling, both of which influence the vascular environment directly.

How long before there is an effect on lipid markers?

The Niranjan trial ran 12 weeks. Lipid changes typically require at least 8 to 12 weeks of consistent supplementation to reflect in bloodwork, because lipid metabolism operates on a cycle measured in weeks, not days.

References

1. Niranjan G et al. Shilajit supplementation in type-2 diabetes: effects on lipid profile and endothelial function. International Journal of Ayurveda and Pharma Research, 2016. https://ijapr.in/index.php/ijapr/article/view/322
2. "Effect of purified Shilajit (Asphaltum punjabianum) on oxidative stress, arterial stiffness and endothelial function in elderly with hypertension: a randomised controlled study." Indian Journal of Physiology and Pharmacology, 2023. https://ijpp.com/effect-of-purified-shilajit-asphaltum-punjabianum-on-oxidative-stress-arterial-stiffness-and-endothelial-function-in-elderly-with-hypertension-a-randomised-controlled-study/
3. Martinez I et al. "Effects of a chromium, Phyllanthus emblica, and shilajit combination on cardiometabolic outcomes." Nutrients, 2025. PMID 40573153. https://pubmed.ncbi.nlm.nih.gov/40573153/
4. Winkler J, Ghosh S. "Therapeutic potential of fulvic acid in chronic inflammatory diseases and diabetes." Journal of Diabetes Research, 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC6151376/
5. Rahmani Barouji S et al. Shilajit inhibition of MCF-7 and MDA-MB-231 breast cancer cells. Nutrients, 2020. PMID 34466597. https://pubmed.ncbi.nlm.nih.gov/34466597/